Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Estrella Immunopharma, Inc. - Common Stock
(NQ:
ESLA
)
2.300
-0.030 (-1.29%)
Streaming Delayed Price
Updated: 2:41 PM EDT, Oct 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Estrella Immunopharma, Inc. - Common Stock
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
October 06, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
June 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
June 03, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
March 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
February 21, 2025
From
Estrella Immunopharma
Via
Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
February 19, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
September 27, 2024
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
August 14, 2024
From
Estrella Immunopharma, Inc.
Via
Business Wire
BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination
October 04, 2023
Via
Investor Brand Network
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today